THE VAULT · GOVERNANCE DOSSIERS · EDUCATIONAL USE ONLY
Read the diligence report before the buyer writes it.
The Vault is where Valmarga releases full-length governance dossiers; fictional companies built from the real patterns that quietly reprice mid-market deals. No sales pitch. Just the findings a buyer’s diligence team reaches on their own, and what it costs to be discovered rather than disclosed.
I. Currently in the Vault
MOCK CASE STUDY · EDUCATIONAL USE ONLY.
DOSSIER 001 — EXIT READINESS · GOVERNANCE DILIGENCE.
PharmaCoSim, Inc.
US PHARMACEUTICAL · SPONSOR-TO-SPONSOR EXIT · T-12 TO CLOSE
The buyer will find everything. The only question is whether you got there first.
PharmaCoSim is fictional. Its findings are not — they are the patterns that reprice real mid-market pharma exits every year. This dossier walks a healthcare-focused PE sale backward from the buyer’s first week in the data room: the undisclosed DOJ Civil Investigative Demand sitting outside the litigation schedule; the active FDA consent decree with two open monitoring gaps; the co-development termination right that could hand the buyer the company without 15–20% of its value; and an LP stack with three independently deal-threatening defects nobody has mapped.
Across 14 governance domains, every finding is sorted into one of three verdicts — and one of three fates: signing blocker, price chip, or delay risk. Then it is sequenced across a 12-month runway, because a GHG inventory commissioned in month four is not verified before the data room opens, and a waiver negotiation that starts too late does not conclude before signing.
14
23
3
T-12
▚ SEALED DOSSIER — DOWNLOAD TO READ
Get the full 31-page dossier.
I. The undisclosed DOJ CID — a day-one warranty breach
II. An FDA consent decree with two open monitoring gaps
III. A termination right worth 15–20% of the valuation
IV. Three deal-threatening defects in the LP stack
THE DOSSIERS IN THE VAULT ARE MOCK CASE STUDIES PREPARED BY VALMARGA ADVISORY FOR EDUCATIONAL AND ILLUSTRATIVE PURPOSES ONLY. THEY ARE NOT DUE DILIGENCE, NOT LEGAL ADVICE, NOT FINANCIAL ADVICE, AND NOT REGULATORY ADVICE. ALL COMPANIES, EXECUTIVES, FIGURES, AND FINDINGS ARE FICTIONAL. NOTHING HERE IS A SUBSTITUTE FOR QUALIFIED LEGAL COUNSEL, A REGISTERED AUDITOR, OR A LICENSED COMPLIANCE PROFESSIONAL.